article thumbnail

Report: Primary Care Physicians Are Addressing Mental Health Concerns More Frequently

MedCity News

The Health Affairs study found that in 2006, 10.7% of primary care visits addressed mental health concerns, compared 15.9% by 2016 and 2018, representing a 50% increase.

article thumbnail

Sandoz to file for approval of aflibercept biosimilar

European Pharmaceutical Review

Sandoz launched its first biosimilar – somatropin (Omnitrope) – in Europe in 2006. The company, a division of Novartis, currently has a portfolio of eight marketed biosimilars, with a further 24 in various development stages.

Safety 94
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Fosun Pharma and IFC to build new drug manufacturing plant in Africa

Pharmaceutical Technology

Since 2006, IFC has repeatedly provided support to Fosun Pharma, which is committed to ensuring the continuous accessibility and affordability of pharmaceutical products and improving the resilience of healthcare supply chains in the region.”

article thumbnail

Study Results Show Estimated 2022 RSV Rates Could Be Twice as High as Previous 2 Years

Pharmacy Times

State-level respiratory syncytial virus hospitalization rates for 2022 could be the highest seen since 2006, analysis published in Frontiers in Pediatrics indicate.

29
article thumbnail

2022 spells change for EU pharmaceutical legislation

European Pharmaceutical Review

Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004 (Text with EEA relevance). Amsterdam: Gupta Strategists; 2019.

article thumbnail

Gilead wins patent battle with US government over HIV PrEP drugs

Pharmaceutical Technology

The CDC had applied for patents back in 2006, and was later granted four in 2015. The government had called for Gilead to “respect the US patent system” and the taxpayer-funded research undertaken by the CDC, per the statement. The November 2019 lawsuit marked a further escalation in an existing dispute.

article thumbnail

Regional inequalities threatening Europe’s biosimilars market

European Pharmaceutical Review

To support biosimilar adoption and expand access for patients in Europe, measures must be taken to reduce the cost of developing biosimilars” Since their introduction in 2006, biosimilars have generated more than €30 billion in cumulative savings for European healthcare systems as of 2022, an IQVIA report from last year highlighted.